Nanobac Pharmaceuticals Releases New Portrait of Calcifying Nanoparticles, Related Announcement to Follow.

TAMPA, Fla. -- Scientists for Nanobac Pharmaceuticals Inc. (OTCBB:NNBP) ("Nanobac" or "the Company") have published a new outlook on the role of calcifying nanoparticles (CNPs) in diseases such as atherosclerosis and kidney stones, setting the groundwork for what company officials call a "significant" announcement next week.

Entitled "What are Calcifying Nanoparticles?" the document on the company's Web site provides, for the first time, investors and journalists with a clear picture of the state of science on CNPs, formerly known as nanobacteria, and summarizes the role CNPs play in one of the most pervasive medical conditions in existence: calcification of arteries and organs.

"We decided to publish this summary so journalists and investors could have a clear idea of what the particles are before we release research next week that will show surprising new results," explained Nanobac Co-Chair Dr. Benedict Maniscalco.

The summary was completed following a conference earlier this month at the University of Auburn, sponsored by the Fetzer Memorial Trust, a non-profit foundation dedicated to bringing leading edge technologies to the forefront.

"After a lot of probing questions from some of the leading scientists in their field, our organization was able to assemble a document that accurately describes the state of knowledge on what CNPs are, what they do to us, and why interest in this pathogen is growing," Dr. Maniscalco added.

For years scientists have been struggling to assemble a snapshot of the "state of knowledge" about CNPs. The document was assembled to fill that gap.

One of the issues raised about CNPs is whether they are any different from calcified crystals that are found in kidney stones and hardening of the arteries.

"Our announcement (including video evidence) next week will show there is a difference, and that difference will explain a lot about why present therapies against calcification have been ineffective," Maniscalco said.

"In preparation for that announcement, and because there have been debates over what the particles actually are, we decided to gather the state of knowledge to date for everybody to see and discuss," he concluded.

Final work is still being done on video microscopy evidence assembled by Nanobac scientists, in preparation for its release next week. The new summary document "What Are Calcifying Nanoparticles (CNPs)?" is available at http://www.nanobac.com/content/what-are-cnps.htm.

About Nanobac Pharmaceuticals: Nanobac Pharmaceuticals Inc. is dedicated to the discovery and development of products and services to improve human health through the detection and treatment of calcifying nanoparticles (CNPs), formerly known as nanobacteria. The company's pioneering research is establishing the pathogenic role of CNPs in soft tissue calcification, particularly in coronary artery, prostate and vascular disease.

Nanobac's drug discovery and development is focused on new and existing compounds that effectively inhibit, destroy or neutralize CNPs. Nanobac manufactures In Vitro Diagnostic (IVD) kits and reagents for detecting calcifying nanoparticles. IVD products include a line of assays, proprietary antibodies and reagents for uniquely recognizing CNPs. Nanobac's BioAnalytical Services works with biopharmaceutical partners to develop and apply methods for avoiding, detecting, and inactivating or eliminating CNPs from raw materials.

Nanobac Pharmaceuticals Inc. is headquartered in Tampa, Florida. For more information, visit our website at: http://www.nanobac.com.

Investors are cautioned that certain statements in this document, some statements in periodic press releases and some oral statements of Nanobac Pharmaceuticals, Inc. officials are "Forward-Looking Statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"). Forward-Looking statements include statements which are predictive in nature, which depend upon or refer to future events or conditions, which include words such as "believes," "anticipates," "intends," "plans," "expects," and similar expressions. In addition, any statements concerning future financial performance (including future revenues, earnings or growth rates), ongoing business strategies or prospects, and possible future Nanobac Pharmaceuticals, Inc. actions, which may be provided by management, are also forward-looking statements as defined by the Act. Forward-Looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements and to vary significantly from reporting period to reporting period. Although management believes that the assumptions will, in fact, prove to be correct or that actual future results will not be different from the expectations expressed in this report. These statements are not guarantees of future performance and Nanobac Pharmaceuticals, Inc. has no specific intention to update these statements.